Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Paragonix Technologies’ advanced organ preservation devices are FDA-cleared and CE-marked for multiple organs. Their technologies have been used in over 10,000 donor cases at more than 180 transplant centers worldwide. Clinical results from the GUARDIAN registries demonstrate improved post-transplant outcomes compared to traditional ice-based methods. The company continues to expand its product line and global reach following its acquisition by Getinge in late Q3 or early Q4 of 2024.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Paragonix Technologies.